Core Viewpoint - The company has not met the performance assessment indicators for the third unlocking period of its 2022 employee stock ownership plan, resulting in no shares being unlocked for this period [8][12][26]. Group 1: Employee Stock Ownership Plan Approval and Implementation - The employee stock ownership plan was approved by the company's board of directors on August 23, 2022, and subsequently by the shareholders on September 9, 2022 [6][27]. - The plan involves a total of 2,950,060 shares, which were transferred to the employee stock ownership plan at a price of 7.50 yuan per share, accounting for 0.51% of the company's total share capital [29]. Group 2: Locking Period and Performance Assessment - The locking period for the employee stock ownership plan is set for a maximum of 36 months, with shares being unlocked in three phases: 30% after 12 months, 35% after 24 months, and 35% after 36 months [9][30]. - The company’s performance assessment for the third unlocking period was based on company-level and individual-level indicators, which were not met, leading to 1,032,521 shares being locked and not unlocked [11][31]. Group 3: Consequences of Not Meeting Performance Indicators - Due to the failure to meet the performance indicators, the shares will be reclaimed by the management committee of the employee stock ownership plan and may be sold to return the investment amount to the holders [12][31]. - If any profits arise from the sale of the shares, those profits will belong to the company [12][31]. Group 4: Future Considerations - The employee stock ownership plan has a total duration of 48 months, and if not extended, it will terminate upon reaching the end of this period [33]. - The company will continue to monitor the implementation of the employee stock ownership plan and fulfill its disclosure obligations as required by law [35].

Group 1 - The core point of the article is that Kew Flower Pharmaceutical has announced the approval of its five-year development plan by the board of directors [2] Group 2 - The announcement was made on the evening of August 12, indicating a strategic direction for the company [2] - The board meeting also reviewed and approved multiple proposals, highlighting the company's proactive governance [2]

Group 1 - The core viewpoint of the news is that Aihua Pharmaceutical (葵花药业) has experienced significant declines in revenue and net profit in its latest quarterly report, indicating potential challenges for the company moving forward [1][3] - As of August 12, 2025, Aihua Pharmaceutical's stock closed at 16.13 yuan, down 0.37%, with a trading volume of 57,200 hands and a transaction amount of 92.5496 million yuan [1] - The company's main funds saw a net outflow of 13.5238 million yuan, accounting for 14.61% of the transaction amount, with large orders contributing significantly to this outflow [1] Group 2 - For the first quarter of 2025, Aihua Pharmaceutical reported total operating revenue of 663 million yuan, a year-on-year decrease of 56.30%, and a net profit attributable to shareholders of 57.1118 million yuan, down 77.62% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 4.148 and a quick ratio of 3.308, while the debt-to-asset ratio stands at 19.49% [1] - Aihua Pharmaceutical has made investments in 32 companies and has participated in six bidding projects, indicating active engagement in business expansion [2]

Group 1 - The company held its ninth meeting of the fifth board of directors on August 12, 2025, via telecommunication, with all nine directors participating in the vote [1] - The board approved the "Five-Year Development Plan Outline" for 2026-2030, which includes the company's mission, vision, strategic positioning, and measures to achieve the goal of "100 billion Kuaihua" [1] - The resolution was passed unanimously with 9 votes in favor, 0 against, and 0 abstentions [1] Group 2 - The strategic committee reviewed the proposal before it was submitted to the board, and it was approved in the first meeting of the strategic committee in 2025 [1]

Core Viewpoint - The third unlocking condition of the 2022 employee stock ownership plan of Kweichow Moutai has not been achieved, resulting in no stocks being unlocked for the period [1][5]. Group 1: Employee Stock Ownership Plan Overview - The employee stock ownership plan was approved on September 9, 2022, during a shareholders' meeting, allowing the company to implement the plan [2]. - A total of 2,950,060 shares were transferred to the employee stock ownership plan, representing a significant portion of the company's total share capital [2]. Group 2: Unlocking Conditions and Performance Metrics - The plan has a duration of 48 months, with three unlocking phases based on performance metrics [3]. - The third unlocking phase required a revenue growth rate of at least 33% compared to the 2021 revenue, which was not met [3][5]. Group 3: Consequences of Non-Achievement - Due to the failure to meet the performance metrics, 1,032,521 shares intended for unlocking will not be released, and the shares will be reclaimed by the management committee [4][5]. - The company will sell the reclaimed shares and return the investment amount to the holders, with any remaining profits going to the company [4][5]. Group 4: Future Arrangements and Compliance - The employee stock ownership plan may be terminated if the shares cannot be fully liquidated before the expiration of the plan [5]. - The company will adhere to market trading rules and relevant regulations regarding stock transactions [5].

葵花药业（SZ 002737，收盘价：16.13元）8月12日晚间发布公告称，公司第五届第九次董事会会议于 2025年8月12日以通讯方式召开。会议审议了《关于公司未来五年发展规划纲要的议案》等文件。 （文章来源：每日经济新闻） 2024年1至12月份，葵花药业的营业收入构成为：医药行业占比99.56%，其他业务占比0.44%。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-050 葵花药业集团股份有限公司 关于 2022 年员工持股计划第三个锁定期解锁条件 未成就的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 葵花药业集团股份有限公司（以下简称"公司"或"葵花药业"）于 2025 年 8 月 12 日召开第五届董事会第九次会议，审议通过《关于 2022 年员工持股计划 第三个锁定期解锁条件未成就的议案》。 鉴于公司 2022 年员工持股计划（以下简称"本员工持股计划"或"本次员 工持股计划"）第三个解锁期公司层面业绩考核指标未达成，解锁条件未成就， 本锁定期目标解锁股票数量为 1,032,521 股，实际可解锁股票数量为 0 股。 根据本员工持股计划规定，本员工持股计划第三个锁定期公司业绩考核指标 未达成，则标的股票权益不得解锁，由持股计划管理委员会收回，择机出售后以 出资金额归还持有人。如返还持有人后仍存在收益，则收益归公司所有。本员工 持股计划所持有的公司股票全部出售，本员工持股计划可提前终止。 根据《关于上市公司实施员工持股计划试点的指导意见》《深圳证 ...

关于葵花药业集团股份有限公司 北京市天元律师事务所 关于葵花药业集团股份有限公司 2022年员工持股计划第三个解锁期 业绩考核指标未达成情况的法律意见 北京市天元律师事务所 中国北京市西城区金融大街35号国际企业大厦A座509单元 邮编：100033 北京市天元律师事务所 2022年员工持股计划第三个解锁期 业绩考核指标未达成情况的法律意见 京天股字（2022）第486-2号 致：葵花药业集团股份有限公司 北京市天元律师事务所（以下简称"本所"）接受葵花药业集团股份有限 公司（以下简称"葵花药业"或"公司"）的委托，就公司2022年员工持股计划（ 以下简称"本次员工持股计划"）第三个解锁期业绩考核指标未达成情况的相 关事宜出具本法律意见。 本所及经办律师依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《律师事务所从事证券法 律业务管理办法》、中国证券监督管理委员会（以下简称"中国证监会"）发布的 《关于上市公司实施员工持股计划试点的指导意见》（以下简称"《指导意见》"） 以及深圳证券交易所（以下简称"深交所"）发布的《深圳证券交易所上市公 司自律监 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-049 葵花药业集团股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"）第五届董事会第九次会议 于 2025 年 8 月 12 日 9 时以通讯方式召开。会议由关玉秀女士召集，会议通知及 议案于 2025 年 8 月 8 日通过电子邮件形式发出。会议应参加表决董事 9 人，实 际参加表决董事 9 人。 公司董事会确定《公司未来五年发展规划纲要》（2026 年-2030 年），系统 性规划公司企业使命、企业愿景、战略定位、战略思想、经营理念、战略方向， 以及实现"百亿葵花"的保障措施等。 表决结果：同意 9 票、反对 0 票、弃权 0 票，通过。 专门委员会审议情况： 本议案提交董事会审议前，业经公司董事会战略委员会 2025 年第一次会议 审议通过。 2、审议通过《关于 2022 年员工持股计划第三个锁定期解锁条件未成就的议案》 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司 ...

Group 1 - The implementation of new childcare subsidy policies in China aims to alleviate the economic pressure on families raising children and demonstrates the government's commitment to promoting long-term balanced population development [1][2] - The childcare subsidy policy is expected to enhance families' disposable income, thereby increasing the demand for pediatric medications and shifting consumption from basic treatment to preventive and multi-scenario medication [2][4] - Leading pediatric pharmaceutical companies, such as Kewang Pharmaceutical, are positioned to capture the increased health consumption demand resulting from these policies, with a comprehensive product matrix covering over 60 pediatric medications [2][3] Group 2 - The development of the pediatric medication industry requires innovation and a strong "blood-making" capability beyond economic subsidies to support long-term population quality development [4][6] - Kewang Pharmaceutical has established itself as a leading player in the pediatric medication sector, investing in R&D and collaborating with Peking University to enhance pediatric drug innovation [4][5] - The company has integrated social responsibility into its business model, conducting extensive public welfare activities and health education initiatives, thereby aligning corporate value with industry value [5][6]